Search results for " FIBRINOGEN"

showing 10 items of 53 documents

The diagnostic performance of renal function-adjusted D-dimer testing in individuals suspected of having venous thromboembolism

2019

Renal impairment, a source of chronic hypercoagulability[1][1] and inflammation,[2][2] is known to reduce the specificity of the D-dimer test in the diagnosis of venous thromboembolism (VTE).[3][3] This leads to many false positives in such patients and consequently to additional costs, as well as

AdultMalemedicine.medical_specialtyComputed Tomography AngiographyRenal functionSensitivity and SpecificityFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineText miningInternal medicineD-dimermedicineFalse positive paradoxHumansFalse Positive ReactionsProspective StudiesRenal InsufficiencyProspective cohort studyOnline Only ArticlesComputed tomography angiographyAgedProbabilityVenous Thrombosismedicine.diagnostic_testbusiness.industryHematologyVenous ThromboembolismMiddle AgedCardiologyFemalebusinessPulmonary EmbolismVenous thromboembolismAlgorithms030215 immunologyGlomerular Filtration RateHaematologica-the Hematology Journal
researchProduct

Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Inst…

2018

: Recommended strategy for venous thromboembolism (VTE) diagnosis includes the use of sensitive D-dimer (DDi) assays along with pretest probability (PTP) assessment. The Clinical and Laboratory Standards Institute (CLSI) recently issued a guideline (US FDA endorsed) on DDi in VTE exclusion. Such guideline specifies the ideal D-dimer assay characteristics and target population. Demonstrate STA-LiatestD-Di performance combined with a PTP score for proximal deep vein thrombosis (pDVT) exclusion in a CLSI compliant study. International, multicenter, prospective nonrandomized, noninterventional clinical outcome management study conducted in a standard-of-care setting. DDi was measured in DVT-sus…

AdultMalemedicine.medical_specialtyDeep veinShort Communications030204 cardiovascular system & hematologySensitivity and SpecificityFibrin Fibrinogen Degradation ProductsSTA-Liatest DDi03 medical and health sciences0302 clinical medicineInternal medicineOutpatientsD-dimermedicineHumansProspective StudiesProspective cohort studyexclusiondeep venous thrombosisAgedVenous ThrombosisUnited States Food and Drug Administrationbusiness.industryImmunoturbidimetryHematologyGeneral MedicineGuidelineMiddle Agedmedicine.diseaseThrombosisUnited StatesPulmonary embolismClinical trialPre- and post-test probabilitymedicine.anatomical_structureD-dimerFemalebusiness030215 immunologyBlood Coagulation & Fibrinolysis
researchProduct

Sex-related differences in D-dimer levels for venous thromboembolism screening.

2021

Background D-dimer is generally considered positive above 0.5 mg/L irrespective of sex. However, women have been shown to be more likely to have a positive D-dimer after controlling for other factors. Thus, differences may exist between males and females for using D-dimer as a marker of venous thromboembolic (VTE) disease. We hypothesized that the accuracy of D-dimer tests may be enhanced by using appropriate cutoff values that reflect sex-related differences in D-dimer levels. Methods This research is a secondary analysis of a multicenter, international, prospective, observational study of adult (18+ years) patients suspected of VTE, with low-to-intermediate pretest probability based on We…

AdultMalemedicine.medical_specialtyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineInternal medicineD-dimermedicineHumansProspective StudiesVenous ThrombosisReceiver operating characteristicbusiness.industry030208 emergency & critical care medicineGeneral MedicineVenous Thromboembolismmedicine.diseaseConfidence intervalPulmonary embolismPre- and post-test probabilityDeep vein thrombosis (DVT)CohortEmergency MedicineFemalebusinessPulmonary EmbolismLower limbs venous ultrasonographyAcademic emergency medicine : official journal of the Society for Academic Emergency MedicineREFERENCES
researchProduct

Postoperative Reduction of Fibrinolysis as a Prognostic Factor of Fatal Outcome

2001

For the resection of an esophagus carcinoma a mortality rate of 2 to 30% was described, It is still unclear whether an abdominothoracic or transhiatal intervention is superior regarding the outcome. To investigate the prognostic value of fibrinolytic markers, plasmin-α2-antiplasmin (PAP) and D-dimer (DD) values were determined daily in the early postoperative period for 11days. In addition, the course of PAP and DD concentrations was compared with the method of esophagectomy. Of the 28 patients enclosed in the study, 5 died between day 10 and day 34 owing to adult respiratory distress syndrome and septicemia. The PAP and DD concentrations increased in survivors after surgery until day 5 an…

AdultMalemedicine.medical_specialtyTime FactorsFatal outcomeEsophageal Neoplasmsmedicine.medical_treatmentReference range030204 cardiovascular system & hematologySensitivity and SpecificityGastroenterologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineInternal medicineFibrinolysisD-dimermedicineHumansFibrinolysinPostoperative PeriodSurvival rateAgedalpha-2-AntiplasminRespiratory distressbusiness.industryFibrinolysisMortality rateHematologyGeneral MedicineMiddle AgedPrognosisAntifibrinolytic AgentsSurgeryEsophagectomySurvival RateROC CurveEsophagectomyFemalebusinessBiomarkers030215 immunologyClinical and Applied Thrombosis/Hemostasis
researchProduct

Dose-Adjusted Thrombosis Prophylaxis in Trauma Surgery According to Levels of D-Dimer

2000

In 234 trauma surgery patients, thrombosis prophylaxis with Nadroparin-Calcium low-molecular-weight heparin (LMWH) was adjusted according to levels of D-Dimer. Basic prophylaxis was 2,850 IU per day. If D-Dimer concentrations rose above 2 mg/L after the fourth postoperative (p.o.) day, LMWH was administered twice a day. Color Doppler ultrasound was performed between the fifth and seventh p.o. days. Patients were divided into a high-risk (group 1: hip, femur, or knee replacement surgery, n=102) and a moderate-risk group (group 2: other surgery of the knee, tibia, fibula, or foot, n=132). Group 1 showed significantly higher D-Dimer levels than group 2 (p0.001). Measurement of D-Dimer on days …

AdultMalemedicine.medical_specialtyTime Factorsmedicine.drug_classmedicine.medical_treatmentDeep veinAntithrombin IIIKnee replacementLow molecular weight heparinSensitivity and SpecificityFibrin Fibrinogen Degradation ProductsFractures BoneRisk FactorsAntifibrinolytic agentD-dimerHumansMedicineAgedAged 80 and overVenous Thrombosisbusiness.industryAnticoagulantNadroparinHematologyMiddle Agedmedicine.diseaseAntifibrinolytic AgentsSurgeryVenous thrombosismedicine.anatomical_structureAnesthesiaWounds and InjuriesFemalebusinessTrauma surgeryBiomarkersLeg InjuriesPeptide HydrolasesThrombosis Research
researchProduct

Laboratory control of minimal heparinization during haemodialysis in patients with a risk of haemorrhage

1994

Abstract For patients undergoing dialysis with a high risk of haemorrhage there is no standardized procedure for anticoagulation during extracorporeal circulation. Minimal heparinization with a dose equivalent to half that used for chronic haemodialysis was employed in 49 patients (125 haemodialyses) performed after operative interventions (83.3%), after haemorrhagic events (5.2%) and after invasive investigations (11.5%). Using a biocompatible membrane and a low molecular weight heparin (bolus dose 500-1300 U; continuous infusion 100-400 U) it was possible to complete haemodialysis in 74 cases (Group 0) without clots appearing in the venous bubble trap of the tubing system. In 30 cases (Gr…

AdultMalemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentAntithrombin IIILow molecular weight heparinHemorrhageFibrin Fibrinogen Degradation ProductsClinical ProtocolsRenal DialysisRisk FactorsmedicineHumansIn patientRisk factorDialysisAgedMonitoring PhysiologicDose-Response Relationship Drugbusiness.industryAnticoagulantExtracorporeal circulationHematologyGeneral MedicineHeparinHeparin Low-Molecular-WeightMiddle AgedAntifibrinolytic AgentsSurgeryFemaleHemodialysisbusinessPeptide Hydrolasesmedicine.drugBlood Coagulation & Fibrinolysis
researchProduct

Evaluation of the Stratus® CS Acute Care™ D-dimer assay (DDMR) using the Stratus® CS STAT Fluorometric Analyzer: A prospective multisite study for ex…

2012

Abstract Background D-dimer testing is an integral part of the diagnostic algorithm in excluding patients with venous thromboembolism. In this study, we prospectively evaluated the Stratus DDMR D-dimer test in patients suspected of pulmonary embolism (PE) and deep vein thrombosis (DVT). Methods Patients suspected of venous thromboembolism were prospectively enrolled at four different clinical sites, with sodium citrate and lithium heparin plasma was tested using the DDMR D-dimer test on the Stratus CS analyzer. Results 1,012 patients were enrolled for analysis, with 85/603 (14.1%) patients with PE and 80/443 (18.1%) with DVT, and four of the patients (0.4%) with PE and DVT. For the samples …

Adultmedicine.medical_specialtyDeep veinGastroenterologyD-dimer assayFibrin Fibrinogen Degradation ProductsYoung AdultInternal medicineAcute caremedicineHumansFluorometryProspective Studiescardiovascular diseasesProspective cohort studyAgedAged 80 and overImmunoassayVenous Thrombosisbusiness.industryHematologyHeparinMiddle Agedmedicine.diseaseThrombosisPulmonary embolismSurgerymedicine.anatomical_structurePulmonary EmbolismbusinessVenous thromboembolismmedicine.drugThrombosis Research
researchProduct

Association Between Carotid Atherosclerosis and Metabolic Syndrome: Results From the ISMIR Study

2010

The metabolic syndrome (MetS) has previously been associated with an early marker of atherosclerosis, the carotid intima-media thickness (IMT). From the ISMIR (Ispessimento Medio Intimale e Rischio cardiovascolare [media-intima thickness and cardiovascular risk]) study population of 479 asymptomatic participants, we identified 80 participants with MetS. Carotid IMT and plaques were evaluated by ultrasonography. Blood samples were obtained from all participants. Participants with MetS had a significantly higher prevalence of a carotid IMT > 0.80 mm (P = .004) and of carotid plaques (P < .001) as compared with participants without MetS. Carotid IMT was significantly correlated with fas…

Blood GlucoseCarotid Artery DiseasesMalemedicine.medical_specialtycarotid intima-media thickness; carotid plaques; fibrinogen; metabolic syndrome; triglyceridescarotid intima-media thicknessFibrinogenAsymptomaticchemistry.chemical_compoundRisk FactorsInternal medicinemedicineHumanscardiovascular diseasesTriglyceridesAgedMetabolic SyndromeCreatinineVascular diseasebusiness.industrycarotid plaquesFibrinogenMiddle Agedmedicine.diseaseUric AcidCross-Sectional Studiesmedicine.anatomical_structureEndocrinologyItalychemistryCreatininecardiovascular systemCardiologyUric acidPopulation studyFemalemedicine.symptomMetabolic syndromeTunica IntimaTunica MediaCardiology and Cardiovascular Medicinebusinessmedicine.drugArteryAngiology
researchProduct

Platelets Contribution to Thrombin Generation in Philadelphia-Negative Myeloproliferative Neoplasms: The "Circulating Wound" Model.

2021

Current cytoreductive and antithrombotic strategies in MPNs are mostly based on cell counts and on patient’s demographic and clinical history. Despite the numerous studies conducted on platelet function and on the role of plasma factors, an accurate and reliable method to dynamically quantify the hypercoagulability states of these conditions is not yet part of clinical practice. Starting from our experience, and after having sifted through the literature, we propose an in-depth narrative report on the contribution of the clonal platelets of MPNs—rich in tissue factor (TF)—in promoting a perpetual procoagulant mechanism. The whole process results in an unbalanced generation of thrombin and i…

Blood PlateletsQH301-705.5platelet functionMPNInflammationReviewDiseaseBioinformaticsFibrinogenModels BiologicalCatalysisPAR receptorLeukemia Myeloid Chronic Atypical BCR-ABL NegativeInorganic ChemistryTissue factorThrombinAntithromboticmedicineAnimalsHumansThrombophiliaPlateletPhysical and Theoretical ChemistryBiology (General)Molecular BiologyQD1-999SpectroscopyPAR receptorsbusiness.industryOrganic ChemistryThrombinGeneral MedicineComputer Science ApplicationsChemistryReceptors FibrinogenCoagulationthrombin generationBiological Assayfibrinogenmedicine.symptombusinessmedicine.drugInternational journal of molecular sciences
researchProduct

C-REACTIVE PROTEIN AND FIBRINOGEN TO EVALUATE THE REAL RISK OF CEREBRO AND CARDIOVASCULAR EVENTS IN PATIENTS WITH DIEBETES MELLITUS

2004

C-REACTIVE PROTEIN FIBRINOGEN
researchProduct